Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 850 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: VA Drug Interactions
Interventions: Midazolam, Delafloxacin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Delirium, Cognitive Impairment
Interventions: Reduced exposure to anticholinergics, Reduced exposure to benzodiazepines, Haloperidol, Usual care; Behavioral · Procedure · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Panic Disorder
Interventions: placebo, alprazolam XR; Other · Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 3
States / cities: Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin

Conditions: Hepatitis C, Chronic
Interventions: midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more

Conditions: Pain, Breast Cancer, Lung Cancer
Interventions: Gabapentin, Lorazepam (active control), Placebo (inactive); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: Delirium
Interventions: olanzapine, placebo; Drug
Lead sponsor: The New England Baptist Hospital; Other
Eligibility: 65 Years and older
Enrollment: 495 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dravet Syndrome
Interventions: Clobazam, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 1 Year to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more

Conditions: Insomnia Disorder
Interventions: Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant-matched placebo., Flurazepam 30 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Crestview Hills, Kentucky

Conditions: Bipolar Disorder
Interventions: Olanzapine, Fluoxetine, Lamotrigine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Lafayette, Indiana

Conditions: Depression, Unipolar, Depression, Bipolar, Suicidal Ideation
Interventions: Ketamine hydrochloride injection, Midazolam injection; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions: Phenobarbital, Lorazepam; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Healthy
Interventions: Orforglipron, Midazolam, Quinidine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Benzodiazepine Refractory Status Epilepticus
Interventions: Fosphenytoin, Levetiracetam, Valproic acid; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 2 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 65
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more

Conditions: Narcotic Use
Interventions: Celecoxib, Hydrocodone-Acetaminophen, Ketorolac, Gabapentin, Acetaminophen, Diazepam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Anxiety Disorder
Interventions: Alprazolam tablet, Alprazolam sublingual; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Sepsis, Trauma
Interventions: Etomidate, midazolam; Drug
Lead sponsor: Advocate Hospital System; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions: Olanzapine, risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 24
States / cities: Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more

Conditions: Epilepsy
Interventions: Alprazolam; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Little Rock, Arkansas • Orlando, Florida • Honolulu, Hawaii + 5 more

Conditions: Generalized Anxiety Disorder
Interventions: Alprazolam (Xanax), Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: sotagliflozin (SAR439954), midazolam, metoprolol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Cancer
Interventions: Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cocaine Dependence
Interventions: Ketamine 0.41 mg/kg, Ketamine 0.71 mg/kg, Lorazepam 2 mg; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 52 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects

Pharmacological Management of Delirium

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Stanford Accelerated Recovery Trial (START)

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression

IM Ketamine vs Midazolam for Suicidal ER Patients

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Established Status Epilepticus Treatment Trial

Nonopioid Analgesia After Labral Surgery

Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

The Effect of Etomidate on Patient Outcomes After Single Bolus Doses

CAFE Comparison of Atypicals in First Episode of Psychosis

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Glutamatergic Modulation of Cocaine-related Deficits